President and Chief Executive Officer
Dr. Joslyn was a partner in Lazarus Pharmaceuticals. Prior to that he served as the Chief Executive Officer and Director of several privately held companies including Edusa Pharmaceuticals and Sentinella Pharmaceuticals and prior to that he was the Senior Vice-President Research and Development of Penwest Pharmaceuticals and also held senior drug development positions with Johnson & Johnson.
Chief Financial Officer
Mr. Sullivan has served as our interim principal executive officer since October 30, 2014 and served as our Chief Financial Officer, Secretary and Treasurer since February 6, 2012. Mr. Sullivan has held senior level financial positions for several publicly and privately held businesses including Utek Corporation, eANGLER, and HSN Direct International Limited. Most recently, he was the Group Financial Officer for the Investigative Services and Litigation Consulting Services segment of First Advantage Corporation. Mr. Sullivan is a Florida Certified Public Accountant. He graduated from the Florida State University with a Bachelor of Science in Accounting and a Master of Business Administration.
Senior Vice President of Discovery Research
Dr. Handfield is, the Company’s Senior Vice President of Discovery Research and previously has served as our Director of Research and Development. Prior to joining our Company, Dr. Handfield held a position as Tenured Associate Professor at the Center for Molecular Microbiology and the Department of Oral Biology at the University of Florida College of Dentistry, where he co-invented IVIAT and co-founded ivi Gene Corp. and Epicure Corp. to commercialize this and related technologies. Dr. Handfield holds a B.S. degree in Biochemistry, and a MS degree and PhD in Microbiology and Immunology from the Université Laval College of Medicine in Canada, and did postdoctoral training at the University of Florida.
January 7, 2021
December 29, 2020
December 24, 2020
November 24, 2020
November 20, 2020
November 19, 2020
October 6, 2020
September 28, 2020
September 11, 2020
August 20, 2020
|OGEN News: Quarterly Report (10-q)||08/09/2022 04:08:29 PM|
|OGEN News: Current Report Filing (8-k)||08/03/2022 04:06:58 PM|
|OGEN News: Statement of Changes in Beneficial Ownership (4)||08/02/2022 04:42:59 PM|
|OGEN News: Amended Annual Report (10-k/a)||07/29/2022 04:03:11 PM|
|OGEN News: Current Report Filing (8-k)||07/08/2022 04:05:16 PM|